Reviva Pharmaceuticals Holdings (RVPH) Assets Average (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Assets Average of $19.7 million for Q1 2026, up 30.5% sequentially from $15.1 million in Q4 2025, and up 74.86% YoY from $11.3 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Assets Average (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Assets Average for 9 years, with the latest figure at $19.7 million in Q1 2026.
- Quarterly Assets Average rose 74.86% year-over-year to $19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 million (up 74.86% YoY) and the FY2025 annual result came in at $15.7 million, down 19.84% from the prior year.
- Assets Average grew to $19.7 million in Q1 2026 per RVPH's latest filing, from $15.1 million in the prior quarter.
- Over five years, Assets Average peaked at $23.0 million in Q2 2022 and troughed at $7.8 million in Q3 2024.
- A 5-year average of $14.7 million and a median of $13.8 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2026: Assets Average slumped 61.44% in 2023, then soared 74.86% in 2026.
- Over 5 years, Assets Average stood at $21.5 million in 2022, then tumbled by 32.3% to $14.5 million in 2023, then declined by 20.47% to $11.6 million in 2024, then jumped by 30.79% to $15.1 million in 2025, then jumped by 30.5% to $19.7 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $19.7 million, $15.1 million, and $13.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | 22.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.35 Mn |
| Mar 31, 2026 | 19.74 Mn |
| Dec 31, 2025 | 15.13 Mn |
| Sep 30, 2025 | 12.98 Mn |
| Jun 30, 2025 | 9.36 Mn |
| Mar 31, 2025 | 11.29 Mn |
| Dec 31, 2024 | 11.57 Mn |
| Sep 30, 2024 | 7.84 Mn |
| Jun 30, 2024 | 10.77 Mn |
| Mar 31, 2024 | 18.60 Mn |
| Dec 31, 2023 | 14.54 Mn |
| Sep 30, 2023 | 8.61 Mn |
| Jun 30, 2023 | 12.37 Mn |
| Mar 31, 2023 | 15.91 Mn |
| Dec 31, 2022 | 21.48 Mn |
| Sep 30, 2022 | 22.34 Mn |
| Jun 30, 2022 | 22.96 Mn |
| Sep 30, 2021 | 35.21 Mn |
| Jun 30, 2021 | 21.60 Mn |
| Mar 31, 2021 | 20.68 Mn |